NASDAQ · BDSI
Healthcare · Drug Manufacturers - Specialty & Generic
$5.59
Down-$0.01 (-0.09%)
Updated Aug 15, 2026, 2:13 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BDSI does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning BDSI.
BDSI research
Company profile and research snapshot.
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 15, 2022 | Piper Sandler | Neutral | — |
| Jan 21, 2022 | HC Wainwright & Co. | Neutral | — |
| Nov 4, 2021 | HC Wainwright & Co. | Neutral | — |
| Aug 5, 2021 | HC Wainwright & Co. | Buy | — |
| Mar 11, 2021 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Zacks Investment Research · Mar 22, 2022
Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.
Zacks Investment Research · Mar 18, 2022
Here is how BioDelivery Sciences International (BDSI) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.
Zacks Investment Research · Mar 17, 2022
Catalyst's (CPRX) fourth-quarter 2021 earnings miss estimates while revenues slightly beat the mark.
Zacks Investment Research · Mar 15, 2022
Incyte' s (INCY) sNDA seeking label expansion of ruxolitinib cream gets extended by three months by the FDA for reviewing additional information.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BDSI.
No results
No recent SID articles mention BDSI.
